For the research, 2000 pet owners were asked whether they they had bought counterfeit pet medicines online. 31.3% said yes. They were then asked if they had reported the matter. 62.2% said they had. Finally, they were asked what the outcome of their report was. 60.9% said their purchase was confirmed as a fake, suggesting that at least one in ten pet owners - probably more - have bought fake pet medicines.
Bayer says the true number of owners affected is likely to be even higher, as a further 12% of pet owners in the survey said they believed that they may have bought fake pet medicines but had not reported it.
The research also showed that 87% of shoppers purchased pet parasite prevention products from unaccredited sites that have been known to sell counterfeit pet medicines. Indeed since April this year, the VMD has removed over 500 veterinary medicine listings from online marketplaces.
The message to clients is that chasing the lowest price for veterinary medicines can be a false economy.
Photo: Can you tell whether this product is fake or not?
Alan, who is MD of the veterinary business consultancy, Vet Dynamics, will be looking at finances, the team, and scoping out a future strategy. The session will provide practical planning tools, strategic advice, and the opportunity to ask questions.
Bayer points to a number of trends which have emerged during lockdown which it says practices must respond to quickly in the post-lockdown recovery.
The company says retailers have reported that internet traffic increased threefold at the start of lockdown and it remains at double the pre-lockdown levels. Direct retail sales of flea and tick products have also increased.
This suggests that owners are becoming more comfortable with buying preventative healthcare products online.
Bayer says there is a business opportunity here for practices. The subscription box market is expected to hit £1 billion by 20222, and one way practices can capitalise on this trend is by offering home-delivered flea, wormer and tick treatments.
Another business opportunity could lie in research by Banfield Pet Hospital among 1,000 US pet owners in which 20% vowed to take their pets ‘more often’ to the vet post-lockdown for preventative care checkups3.
Caroline Braidwood, Regional Business Manager of Bayer Animal Health said: "We know that many veterinary customers have potentially gone elsewhere during the pandemic and vets will need to work hard to win them back. Our webinar will provide tangible insights to ensure that practices can flourish. Whether you’ve worked with Bayer or not, our team of Veterinary Business Managers are here to help. We’re all in this together, and with some planning, we can ensure the veterinary industry continues to grow.”
To book your webinar place, visit: https://event.webinarjam.com/register/46/rk71qav5
Neptra contains florfenicol, an antibiotic which Bayer says is ideal for dealing with the Staphylococcus pseudintermedius found in the majority of otitis externa cases, together with terbinafine hydrochloride, which is effective against Malassezia pachydermatis, and mometasone furoate, a corticosteroid that provides anti-inflammatory activity to improve patient comfort.
A single, 1ml dose in each affected ear treats dogs of all breeds and in trials, continuous clinical improvement was seen until day 28.
Neptra was approved for use in the USA back in 2015, where it has apparently gone down a bit of a storm, becoming the number one product for otitis externa in the country, with over 4.7 million doses prescribed since 2017.
Dr Ken Kwochka, DVM, DACVD, President of the World Association for Veterinary Dermatology (pictured right) said: "This solution is trusted by thousands of vets across the USA, it’s now time for UK vets to benefit from the convenience and confidence Neptra offers. Neptra is the ideal and easier way to treat the majority of otitis externa cases you see and can (and should) be used first-line."
Donna Tomlinson, Senior Brand Manager at Bayer said: "It’s not every day that you’re able to launch a solution that has the potential of Neptra to change treatment practices for the better and improve outcomes for dogs. Across the UK and Europe, our brilliant team at Bayer have put months of effort into this launch and developed an exciting marketing support package. Our veterinary business managers are already out on the road, ready to talk to you all about it."
Neptra is available now to order as one SKU via your regular wholesaler or speak to your Bayer veterinary business manager.
Practice support materials are also available via www.vetcentre.bayer.co.uk.
Neptra has been approved for the treatment of acute canine otitis externa or acute exacerbations of recurrent otitis caused by mixed infections of susceptible strains of bacteria sensitive to florfenicol (Staphylococcus pseudintermedius) and fungi sensitive to terbinafine (Malassezia pachydermatis), by the European Commission.
Mario Andreoli, Head of Marketing at Bayer Animal Health, said: "Otitis externa is a common disease in dogs and a leading cause why owners take their dog to a veterinarian.
"Neptra offers a key advantage, unlike competing products, it requires just one dose, administered by the veterinarian in the practice."
No at-home applications by the dog owner are required. The treatment stays in the hands of the vet who has full control over compliance.
Mario added: "With Neptra we provide a high-quality veterinary treatment that is convenient for the dog owner and ensures the well-being of dogs with a proper, effective application."
VetSurgeon understands the new product will be available in the UK in January 2020.
It might explain why, according to the research, around 14% of British adults actively encourage fox visitors into their garden, with 10% of adults leaving out food, water or toys for foxes and 48% of them admitting they would feel disappointed if their garden fox did not return at night.
Bayer highlights research which showed an increase in the number of foxes infected with Angiostrongylus, from 7.3% in 2008 to 18.3% in 20152,3.
More recent work led by the aptly named Professor Mark Fox at the Royal Veterinary College has shown that, in the Greater London area, nearly three out of four foxes (74.4%) are infected with the parasite.4
Mark said: "We had previously mapped the distribution of Angiostrongylus in pet dogs by seeing how many cases every small animal practice in Britain had seen over the previous 12 months. This revealed the parasite’s widespread distribution coupled with hotspots of infection in Greater London/south-east England and South Wales, where dogs were four to five times more likely to be infected than elsewhere in the country.
"We then investigated why hot spots were seen in these locations and, apart from land type, dog density and climatic factors, we found that the mere presence of foxes locally increased the risk of infection in dogs five-fold."
"The overall prevalence of infection in Greater London was very high, at just under 75 per cent4, and prevalence was maintained at this level throughout the year. These results suggest that foxes act as year-round, wild animal reservoirs of infection for urban dogs."
Donna Tomlinson, Bayer Senior Brand Manager said: "The recent ‘pet foxes’ pet owner research results coupled with the lungworm prevalence fox studies highlights the growing concern of the spread of Angiostrongylus vasorum in the UK and the need for adequate preventative measures for pet dogs.
"Veterinary professionals are perfectly placed to advise dog owners on the risk of their pets becoming infected with the parasite, including the growing role of foxes as potential wild animal reservoirs of Angiostrongylus, as well as advising pet owners to use a monthly spot-on prevention such as Advocate.
"Treatment with products containing moxidectin, such as Advocate, not only kills lungworms present at the time of treatment but also kills larvae after ingestion preventing new infections. Regular monthly use prevents disease and ensures that no lungworm larvae are shed in dogs’ faeces which helps to prevent the spread of the parasite in the environment."
To highlight the increased prevalence of lungworm in foxes Bayer has created a poster for veterinary practices, which you can get from the Bayer Vet Centre at: https://www.vetcentre.bayer.co.uk/marketing-and-resources/advocate-fox-poster
References
Baycox Iron Injection is indicated for the concurrent prevention of clinical signs of coccidiosis (such as diarrhoea) in neonatal piglets on farms with a confirmed history of coccidiosis caused by Cystoisospora suis, and the prevention of iron deficiency anaemia.
Professor Nicole Kemper, Director of the Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour at the University of Veterinary Medicine Hannover in Germany said: "Piglets go through intense handling in their first days of life. While this is done to give them a better start to life and protect them from disease, it can also cause a lot of stress. Measures to reduce the need for piglet handling can make an important contribution to enhancing piglet well-being in the farrowing pen."
Octavio Orlovsky Eckhardt, Head of Species Marketing Swine at Animal Health, Bayer said: "A combination therapy that can effectively address these concerns with reduced handling can make a real difference for pig health and well-being.
"At the same time, farmers and workers can benefit from the reduced labour. For example, on a 1,000 sow farm, the reduced complexity is estimated to save up to one full work day every month."
For more information on Baycox Iron Injection, contact your local Bayer Animal Health representative.
The two companies have agreed to jointly discover and develop species-specific therapeutic monoclonal antibodies for companion animals, a class of drug which they say is neglected in veterinary medicine but offers a variety of future therapeutic options for diseases that cannot be adequately treated today.
adivo will select species-specific antibodies using its proprietary fully canine phage display library. Bayer Animal Health will provide targets involved in severe animal diseases.
Dr. Douglas Hutchens, Bayer Animal Health’s Head of Drug Discovery, External Innovation & Chief Veterinary Officer, said: "Today’s agreement is another example of how we realize our innovation strategy
"By combining the know-how from creative start-up companies like adivo with opportunities derived from Bayer’s research, we broaden our space of therapeutic medicine options and complement our portfolio.
"We are constantly looking for innovative technologies that enable us to generate novel treatment options for the companion animal sector. Now, we will focus on evolving the options presented by adivo from research and development to market maturity."
Dr. Kathrin Ladetzki-Baehs, Managing Director of adivo said: "At adivo, we truly believe that pets have a positive impact on our society. By developing novel medicines for companion animals, we want to make a difference for veterinarians and pet-parents. Today, we are more than pleased and excited to have gained such a committed and experienced collaboration partner, to jointly develop new treatment options."
Canine leishmaniosis is caused by the protozoan Leishmania infantum, which is found in most continents1. L. infantum is most commonly transmitted through the bite of sand flies and Bayer says there is a growing concern among parasitologists that the distribution of the disease is increasing due to climate change and more frequent pet travel.
Dr. Markus Edingloh, Head of Global Veterinary Scientific Affairs at Bayer Animal Health, said: "We are seeing more cases of canine leishmaniosis in areas where the disease had not previously been found. Dogs travelling and imported from endemic areas are of particular concern for introduction of the disease, while climate change is contributing to the spread of the vector.
It is therefore vital that veterinarians are aware of the disease and are recommending appropriate protection for dogs travelling to, or living in, endemic areas."
In dogs, there are a wide range of potential clinical signs associated with leishmaniosis including generalised lymphadenopathy, weight loss, lethargy, pyrexia, cutaneous lesions, ocular lesions and neurological or vascular disorders, while the severity of disease can vary from mild to life threatening2,3. In humans L. infantum tends to be responsible for the most severe form of leishmaniosis, visceral leishmaniasis, which can be fatal.
While distribution is worldwide, L. infantum is particularly prevalent in South America and the Mediterranean, with annual cases of zoonotic visceral leishmaniasis in people estimated to be 3,500 in Brazil and 875 in the Mediterranean1.
In some areas, over 80% of canine leishmaniosis cases may be asymptomatic1. However, the infection level in asymptomatic dogs is such that these dogs, in addition to the dogs showing clinical disease, can still be responsible for the spread of disease4. Therefore protection against infection to help control spread is vital for both human and dog health, as clinical cases will not always be obvious.
The non-profit scientific association, LeishVet, recommends that prevention should include the use of a long-acting topical insecticide throughout the period of sand fly activity: "Long-acting topical insecticides applied to dogs living in or travelling to endemic areas should be maintained during the entire risk period of potential exposure to/or activity of sand flies."
Bayer says that Seresto, which contains imidacloprid and flumethrin in a slow release collar, has been found to significantly reduce the risk of infection with Leishmania infantum in dogs for up to eight months. Three clinical field studies, performed in endemic areas, indicated a significant reduction in the risk of Leishmania infantum transmission by sand flies in treated dogs compared to non-treated dogs. The efficacy in the reduction of the risk of infection with leishmaniosis ranged from 88.3 to 100% 5,6,7.
For more information, visit www.vetcentre.bayer.co.uk/seresto.
A survey carried out by the company in 20151 found that 46% of dog owners were not aware that dogs can potentially suffer from the condition, despite the fact that it affects an estimated 375,000 dogs in the UK.3
The company says ocular conditions account for around one in ten canine consultations in first opinion practice,2 with KCS affecting around 5% of all dogs3, and up to 20% of predisposed breeds.4
To help raise owner awareness, Bayer will be holding the first veterinary Dry Eye Awareness Month in July.
Because early diagnosis and treatment can have a significant impact on prognosis, the focus of the campaign will be on encouraging pet owners to speak to their veterinary surgeon in the hope of increasing early diagnoses and improving the uptake of regular testing of at-risk breeds.
The campaign will include a dedicated social media element, targeting communities of at-risk breeds by inviting them to pledge their commitment to managing dry eye in their pet. A range of practice materials have also been produced for practices to support the drive in their waiting room.
Hannah Watts, Group Product Manager at Bayer said: "With this significant gap in owner understanding of the significance of KCS in dogs, it was clear that more is needed to be done to encourage owners of at-risk breeds to visit their vet practice for early diagnosis.
"The focus of Dry Eye Awareness Month is to support vets in championing the issue amongst their client base, through a range of educational materials. We hope vets will join us in utilising the month as a platform on which to discuss the prevalence and potential seriousness of the condition if left unmanaged."
Bayer’s research also found how poor understanding of the lifelong nature of the condition is one of the main barriers to owner compliance when managing cases, further highlighting the need for education.5
Chris Dixon, Director at Veterinary Vision Ophthalmic Referrals, said: "KCS cases can present acutely, or with subtle clinical signs that will not be detected from initial observations and require a Schirmer tear test to effectively quantify the reflex tear film production. Unless vets are actively discussing the condition with owners, and performing these tests on a regular basis, it is likely that many dogs could remain undiagnosed."
"In any case where ongoing treatment is required, client education is key in successful disease management. Accurate determination of the cause of the KCS will allow for an appropriate choice of medical therapy. When adjunctive tear replacement therapy is required, many owners will admit to not having the time to administer treatments frequently enough, which should factor into the recommendations we make as practitioners. For example, offering a longer acting product which requires less frequent application.”
You can download the Remend ‘Vision Matters – A Focus on Keratoconjunctivitis Sicca’ educational guide for veterinary surgeons here: www.remend.co.uk/vets-area.
Dry Eye Awareness Month practice display materials can be ordered from your Bayer Territory Manager or email: ahmarketing@bayer.com
Bayer Animal Health, maker of Advocate, says that since February, veterinary surgeons have reported more than 80 cases of canine lungworm infection in the UK, of which six have died.
The fatal cases were reported in Salisbury, Crawley, Ipswitch and Essex.
Of the 84 cases reported, 43 practices said it wasn't their first. With no requirement for compulsory reporting, Bayer says it is likely that other cases have gone undocumented.
Although the majority of cases reported to Bayer were found in the South of the UK, others were reported as far north as Paisley in Scotland. This, says the company, adds to the increasing base of evidence that lungworm is endemic throughout much of the UK and continues to pose a significant threat to dogs.
Recent research by Bayer found that 37% of veterinary surgeons thought cases of lungworm had increased in their area over the last five years.2
The company also points towards a study from the University of Bristol which examined the fox population and found further evidence of the parasite's spread across the UK.3 The research suggests that the overall prevalence of A.vasorum in foxes is 18.3% in the UK, significantly higher than a previous study published in 2008, which reported a prevalence of 7.3%.3
The South East is reported to have the highest prevalence, with 50% of foxes now found to be infected (more than double the previous figure). In the North of England and Scotland, 7.4% of foxes were found to be infected despite none being found in this region in the earlier study.
Dogs which have picked up a lungworm infection can show a number of different symptoms including breathing difficulties, a lack of energy, coughing and persistent bleeding. However, the clinical signs can be varied and some dogs may appear healthy in the early stages of infection.
Gavin McAulay, a cardiorespiratory specialist at New Priory Veterinary Hospital in Brighton said: "With often confusing symptoms, the clinical judgement of vets is key in ensuring an animal is diagnosed and treated against lungworm as soon as possible. In many scenarios lungworm should be a consideration to be assessed in the background whilst investigating other conditions, however monthly prevention is key. There is evidence with other parasite diseases that suggests the more animals you treat, the better protected other animals in the area are."
Bayer’s 'Act Against Lungworm' campaign is urging veterinary surgeons to encourage monthly lungworm preventative treatment. Prevention which stops larval shedding will also help limit the geographical spread of the disease.
Donna Tomlinson, Senior Product Manager for Advocate said: “With the continued spread of lungworm in the UK, it is important to ensure that our 2017 ‘Act Against Lungworm’ campaign resonates with local communities. We have the case studies to show that lungworm has been reported across the UK, but we rely on the support of vets to help get the message out.
"This year we are putting local vets at the center of our communications, with dedicated campaigns planned in every region. This is a great opportunity for practices to get involved in a local media campaign, talk about their first-hand experiences with the parasite and encourage pet owners to visit them for advice on preventative treatment.”
Veterinary surgeons can report cases to their local Bayer Territory Manager or practices can log their own incidences directly by emailing lungworm@bayer.com.
'Act Against Lungworm' veterinary campaign materials are available for practices to display in waiting rooms, as well as leaflets to assist practitioners in communicating to dog owners the importance of protecting their pet against lungworm. These can be ordered at the Bayer Vet Centre (www.vetcentre.bayer.co.uk).
References:
It's just over a year since microchipping became compulsory for dogs and according to Defra, 95% of dogs are now chipped.
However, the PDSA PAW Report 2016 showed that only 20% of Britain's 11m cats live an indoor-only life, meaning that there are 9 million 'free-range' cats at risk of getting lost if they stray too far from home.
The PDSA report also found 91% of veterinary professionals in the UK believe microchipping should be compulsory for cats.
Bayer says that advice to dog owners this year should focus on the importance of keeping their chip registration details up to date, after a BVA survey found 44% of veterinary surgeons still cannot reunite missing or stray dogs with their owners due to incorrect chip information being stored on the databases.1
Hannah Watts, Product Manager at Bayer said: "Until microchipping becomes compulsory in cats, vets will need to play a crucial role in helping increase the number of UK cats that are microchipped. National Microchipping month provides a great opportunity for vets to raise the subject with owners and to take advantage of the increased awareness and interest in the subject throughout June. With so many dogs now microchipped, ensuring owners are aware of the need to update their details on the microchipping database is an equally important educational message for vets to convey."
Bayer says that during National Microchipping Month, it will be actively driving pet owners into veterinary practices across the country to discuss the benefits of microchipping with their veterinary surgeon. It will also be trying to ensure pet owners understand the importance of keeping the details stored on their pet’s microchip database up to date.
To help drive home the message, Bayer has also developed a range of new marketing and support materials for practices to display throughout June.
To order National Microchipping Month support materials, visit www.vetcentre.bayer.co.uk or speak to your Bayer Territory Manager.
Reference
The guide reviews the definition and classification of pyoderma, history-taking and clinical examination, and diagnostic testing techniques. It also reviews current thinking on therapy options. Bayer says it hopes the practical and evidence-based guide will be an invaluable resource in veterinary practices.
Ross said: "With pyoderma cases appearing almost daily in veterinary consultations, it is vitally important that vets are well versed in treating cases appropriately and efficiently, particularly to ensure the responsible use of antimicrobials. Canine pyoderma commonly poses diagnostic challenges, due to its varied clinical presentation and tendency to be super-imposed on other skin diseases. We envisage that the article will provide readily accessible, clear and practical advice on diagnosing and treating the condition."
Bayer has also launched a new Veraflox website, where the first and second guides in the Education Now, Safeguarding Antimicrobials series (written by Simon Tappin, Head of Medicine at Dick White referrals, Matt Jones, Head of Microbiology at IDEXX, and Ross Bond), are also available for download in the Vet Training Centre section.
The website also offers a number of other resources in the Vet Training Centre, including webinars, case studies and videos.
Hannah Watts, Group Product Manager at Bayer, said: "The new Veraflox website has been built with the practical needs of vets in mind. We hope this will become a frequent resource for helping them overcome daily challenges in diagnosing and treating cases with an appropriate antimicrobial product."
In addition to being available for download at www.veraflox.co.uk, Focus on Pyoderma is also available in print by contacting your Bayer Territory Manager.
The founders of ioLight, Andrew Monk and Richard Williams, will be in attendance on the Bayer stand to answer questions about the new product.
James Crawford, Head of Marketing at Bayer, said: "Bayer is delighted to present the ioLight microscope on our stand at the London Vet Show 2016. The microscope provides fantastically clear images and is simple to use, showing off Bayer's products for all our customers to see."
Professor Mike Taylor, a Diplomate of the European Veterinary Parasitology College, is in the process of evaluating the ioLight microscope as a tool for the diagnosis of parasitic infections of farm animals.
Normally he uses a laboratory microscope for this work but they are not routinely used on a farm. He has also tried a portable digital microscope, but finds it does not give the resolution required for identification of protozoan parasite species or for counting nematode eggs. Mike said: "The ioLight’s portability, image quality and connectivity to the Apple iPad offer great potential for the development of rapid methods for identifying parasites, or determining parasite burdens. I can envisage its use by both veterinarians and suitably trained livestock farmers, in the practice laboratory or directly on the farm."
Andrew Monk said: "Since our launch earlier this year we have seen a massive interest from the veterinary sector. We are thrilled to have the opportunity to demonstrate our microscope to such a large audience, and are looking forward to working with Bayer."
For more information visit iolight.co.uk or email Andrew Monk at andrew.monk@iolight.co.uk.
The 15 minute video (see below) is hosted by Chris Dixon, veterinary ophthalmologist and director at Veterinary Vision Ophthalmic Referrals, who discusses things to consider when examining a patient with an ocular disorder. He offers practical advice on how to perform an ocular examination, including tips on how to use an ophthalmoscope effectively, examining the ocular structures including the front eye, distant direct examination, indirect examination and close direct examination.
Chris said: "This series of videos aims to help vets learn how to perform the fundamental techniques of ophthalmic examination, hopefully enabling them to spot potentially degenerative conditions earlier. The second video in particular delves into practical tips that vets can use within practice. The videos have been created in partnership with Bayer as part of their ongoing commitment to training, and aim to help ensure that chronic conditions, such as keratoconjunctivitis sicca (KCS), or dry eye, are diagnosed and treated early."
The veterinary practice waiting room display materials are designed to help practices educate dog owners on the signs and management of Dry Eye in the hope that the condition may be diagnosed and treated earlier and to emphasise the importance of ongoing treatment and management.
Hannah Watts, Group Product Manager at Bayer said: "It is important that dog owners with a predisposed breed are aware that their pet may be at risk of developing Dry Eye and are aware of the symptoms. Annual testing in at risk breeds for Dry Eye is recommended to help reach an early diagnosis and optimise the chances of a successful treatment outcome."
The Dry Eye practice display materials are available to order via the Bayer Vet Centre www.vetcentre.bayer.co.uk. Alternatively, ask your Bayer rep for more details.
fVtqNMj35c8
Hosted by Chris Dixon, veterinary ophthalmologist and director at Veterinary Vision Ophthalmic Referrals, the Back to Basics series highlights key aspects to consider when examining a patient with an ocular disorder.
Each 15 minute video covers different aspects of the ocular examination, including practical tips for performing an external and internal ocular exam, optimal use of the ophthalmoscope, and how to approach and manage two common ocular conditions in dogs: corneal ulceration and keratoconjunctivitis sicca.
In the first video of the series, Chris discusses how to perform an external ocular examination, and demonstrates some key ocular reflex and response tests, including the menace response, dazzle reflex, and pupillary light reflex.
Chris said: "This series of videos aims to help vets learn how to perform the fundamental techniques of ophthalmic examination, hopefully enabling them to spot potentially degenerative conditions earlier. The videos have been created in partnership with Bayer as part of their ongoing commitment to training, and aim to help ensure that chronic conditions, such as keratoconjunctivitis sicca (KCS), or dry eye, are diagnosed and treated early."
Hannah Watts, Group Product Manager at Bayer said: "Ocular conditions are commonly encountered in practice, and early diagnosis of conditions such as keratoconjunctivitis sicca (KCS) is so important; with this in mind, the aim of these videos is to assist vets in their approach to the canine ocular examination, in order to allow them to feel confident in diagnosing and managing common ocular conditions."
The first video is available below. Don't forget that you can use the 'Claim CPD' button above this story to claim time spent watching it towards your annual CPD requirement.
The videos have been launched as part of the RemendTM Vision Matters campaign.
uiOVleUalo
Described as a first-of-its-kind, mobile-enabled digital whitepaper, the publication offers veterinary surgeons and farmers a resource on ketosis, scientific insights on the impact of the disease, and tools to help optimize dairy herd management.
According to the company, the whitepaper reveals that ketone bodies play a more significant role in metabolic diseases than was previously realized, and that beta-hydroxybutyrate is a good indicator of the presence of subclinical ketosis in dairy cattle.
Rinse Boersma, Dairy Species Manager, Animal Health, Bayer said: "Recognizing the significance of ketone bodies is a positive step towards further enhancing dairy cattle health and welfare. Veterinarians can now reliably detect the presence of subclinical ketosis in dairy herds with a simple blood test, and act quickly with the appropriate corrective measures to arrest disease progression."
Also at Congress, Bayer revealed its enhanced BCS Cowdition smartphone application, designed to support ease and accuracy of body condition scoring (BCS) of dairy cows. Bayer says the upgrade helps farmers to improve herd health management by enabling assessment of individual cows’ BCS scores based on its lactation cycle, alerts for cows that need to be attended to, and a dashboard that offers farmers an overview of their entire herd’s health.
BCS Cowdition is available in 10 languages and is free for download from the AppStore and GooglePlay.
The guide has been written by Simon Tappin, European and RCVS Recognised Specialist in Veterinary Internal Medicine at Dick White Referrals, and is designed to offer practical advice on the appropriate use of antibiotics in general practice. It covers a range of topics including how to create an antibiotic practice policy, ways to optimise therapy and how to limit the development of antimicrobial resistance.
Simon said: "Making rational and informed antimicrobial choices is vitally important in veterinary medicine, both for the welfare of our patients and in reducing the risk of developing antimicrobial resistance.
"Highlighting this issue to vets, providing education and supporting them in making these decisions is crucial to ensure a responsible approach to antimicrobial prescribing."
Recent surveys have highlighted the need for education on this topic, with 63 per cent of vets1 stating that they would like to improve their knowledge on antimicrobials, and 90 per cent of vets2 admitting that they are concerned about antimicrobial resistance.
In addition, there's a quiz where you can test and your knowledge on antimicrobials, and enter a competition to win an iPad Pro. The quiz can be accessed at https://veraflox.typeform.com/to/KY8lxX.
The guide is available from the Bayer Vet Centre, www.vetcentre.bayer.co.uk. Alternatively, you can download it here www.bit.ly/Veraflox2016 or contact your local Bayer Territory Manager.
Bayer Animal Health has been enjoying considerable success in its efforts to raise awareness of the danger of lungworm amongst pet owners.
The company signed model and 'Strictly Come Dancing' presenter Tess Daly to front it's Be Lungworm Aware campaign at Crufts this year.
Coincidentally, her previous involvement in the Be Lungworm Aware campaign has led her to believe that her Golden Retriever, Sam, died of lungworm.
She said: "Back then I didn’t even realise lungworm existed. It was only subsequently that I became aware of the parasite and symptoms and I thought, ‘hang on this sounds horribly familiar’.
"It wasn’t confirmed what was causing Sam’s symptoms, but he was very tired, off his food and coughing a lot. Eventually we had to send him to a specialist vet centre as his symptoms worsened. They did all sorts of tests on him, and even a blood transfusion in an attempt to save his life, it was awful. We had to liquefy all his food and feed him through a syringe, and by this point he was vomiting and had severe diarrhoea, and in the end we had no choice but to put him down, he just couldn’t carry on."
Tess's involvement in the campaign is definitely paying dividends in raising awareness. Here she is talking about it in a Daily Telegraph video. There's also a piece in What's on TV. And although the Daily Mail seems more interested in her 'casual but slick ensemble', the photographs get the message across and there's a video there too.
Bayer has also launched an interactive lungworm map to assist with plotting the prevalence of the disease across the UK. The company says it is part of a wider research programme to better monitor and document the spread of the disease. Vets are asked to report cases of lungworm in their practices to be added to the map, so dog owners can then view reported cases of lungworm in their area at www.lungworm.co.uk.
Bayer Animal Health has launched its annual tick awareness campaign, this year titled 'No Bite is Right', with results of a survey which found that 44% of pet owners don't use regular preventative tick treatment.
The OnePoll survey of 4000 pet owners, which was conducted on behalf of the company in January, also found that 60% of pet owners are worried about ticks spreading disease to their pet, and 28% have found one.
As part of the 'No Bite is Right' campaign, owners are being encouraged to speak to their veterinary surgeon about using preventative tick products to help reduce the risk of their pet becoming infected by tick-borne diseases.
Jenny Helm, University of Glasgow Veterinary Clinician, said: "In recent years I have noticed and been made aware from owners and other vets, of a steady rise in tick numbers across the country. With this there is an increased risk of potentially fatal tick-borne diseases being transmitted to pets. However, if a tick can be killed before it bites, this avoids the risk and provides vital protection to the pet."
Richard Wall, Professor of Zoology at Bristol University, said: "Research has shown that in recent years, tick abundance has increased and the period of seasonal activity has extended in many areas. Climate change, particularly warmer, wet winters have had direct effects on tick feeding as well as impacting indirectly on vegetation cover and creating a more suitable habitat. The increase in deer numbers, habitat modification by conservation and changes in farming practices have also all contributed to the growth in numbers."
Stella Huyshe-Shires, from charity Lyme Disease Action, says: "Lyme Borreliosis is a rapidly emerging disease in the UK and a number of experienced healthcare professionals believe the increase in reported cases reflects a genuine rise over the last 20 years, and not just increased awareness leading to more diagnosis. There appears to have been an increase in ticks and, in turn, an increase in the prevalence of Lyme borreliosis in ticks."
'No Bite Is Right' is part of Bayer Animal Health’s wider 'It’s a Jungle Out There' parasite protection initiative. A series of campaign roadshows for pet owners will be taking place this year at the Ayr, Devon and New Forest County Shows. You can find out more about how your practice can get involved with the campaign by following the conversation on www.facebook.com/jungleforpets and downloading campaign materials at www.vetcentre.bayer.co.uk.
Bayer Animal Health has announced the launch of three new educational videos which look at some common concerns in the profession about antimicrobials, including owner compliance, laboratory testing, and prescribing policies in different clinical scenarios.
The videos follow research conducted by Bayer as part of its Veraflox What Lies Beneath campaign in which 73% of veterinary surgeons cited owner compliance as a frequent cause of treatment failure when tackling bacterial infections, and only 5%1 of vets said that they send samples for culture and sensitivity testing routinely in cases where they suspect bacterial involvement.
In the first video presentation, Matt Jones, Microbiology Manager at IDEXX Laboratories, focuses on the importance of culture and sensitivity testing, and how to interpret results from these tests. Matt discusses the merits and drawbacks of various testing techniques available, both in-house and from external laboratories.
In the second presentation, Liz Watkins, founder of Chunk Training, a veterinary training provider which specialises in customer service, provides communication tips to improve consultation technique and increase owner compliance when a course of antimicrobials has been prescribed.
In the final presentation, Ian Battersby, Recognised Specialist in Small Animal Internal Medicine at Davies Veterinary Specialists answers commonly asked questions submitted by vets about antibiotics. Questions include how to adopt a practice antimicrobial policy, how to decide when it is appropriate to use antibiotics in GI disease and how to approach cases that are not responding as expected to antimicrobial treatment.
Hannah Watts, Group Product Manager at Bayer said: ‘‘The issues highlighted by the research need to be addressed in order to help promote responsible antimicrobial use. One of the key findings from the survey was the relatively low number of culture and sensitivity tests that are routinely performed. This may in part be due to financial constraints, but in addition to assisting in appropriate antimicrobial selection, culture and sensitivity tests often save money for the client in the long run, as well as helping to resolve the condition as quickly as possible, leading to improved treatment outcomes for the pet.‘’
Watching the videos can be used to count towards your annual CPD requirement. They're now available at www.vetcentre.bayer.co.uk.
Bayer Animal Health has announced changes to the product indications for Baytril 50mg/ml and 100mg/ml Solutions for Injection, which both contain enrofloxacin.
Baytril 50mg/ml and 100mg/ml Solutions for Injection, now have licensed indications for the treatment of sheep and goats.
Baytril 50mg/ml and 100mg/ml* Solutions for Injection are now licensed for the treatment of acute mycoplasma-associated arthritis due to enrofloxacin- susceptible strains of Mycoplasma bovis in cattle (*in cattle less than 2 years old.)
For the treatment of acute severe mastitis caused by enrofloxacin - susceptible strains ofEscherichia coli in cattle, the second injection of Baytril 100 mg/ml Solution for Injection may now be given subcutaneously, 24 hours after the first dose administered by intravenous injection. In this case, the withdrawal period following subcutaneous injection should be applied.
For more information, refer to the product data sheets at www.noahcompendium.co.uk and SPCs or speak to your local Bayer Animal Health representative.
Bayer Animal Health has announced the launch of, Dinalgen (ketoprofen), an NSAID injection approved for use in cattle, pigs and horses.
Dinalgen is available as a 150mg/ml Solution for Injection, and Bayer says the more concentrated format allows the product to provide the smallest dose, fast relief NSAID currently available for cattle in the UK.
In cattle, Dinalgen is licensed for the reduction of inflammation and pain associated with lameness, post-partum, and musculoskeletal disorders; the reduction of fever associated with bovine respiratory disease; and the reduction of inflammation, fever and pain in acute clinical mastitis in combination with antimicrobial therapy where appropriate. The withdrawal period for milk is zero hours and for meat two days.
In pigs, Dinalgen is licensed for the reduction of pyrexia in cases of respiratory disease and postpartum dysgalactia syndrome in sows, in combination with antimicrobial therapy.
In horses, Dinalgen is licensed for the reduction of inflammation and pain associated with osteoarticular and musculoskeletal disorders, including lameness, laminitis, osteoarthritis, synovitis, and tendinitis. It also aids the reduction of visceral pain associated with colic.
Sharon Cooksey, MRCVS, FAP group product manager at Bayer, said: “We are excited to have this new addition to our portfolio. It is a good fit with our existing products.
"A recent field study*, carried out by Nottingham university, has shown that NSAID (ketoprofen) treatment maximises the chance of recovery from lameness in dairy cattle. Lameness remains one of the “big three” issues in dairy practice so maybe it is time we moved on from hoof blocks and/ or trimming in isolation and onto a more multi-layer approach. We have some great support tools in the pipeline to help both vets and farmers recognise and manage animals at risk for lameness.”
For further product information visit www.noahcompendium.co.uk or contact your local Bayer territory manager.
Bayer Animal Health has announced the launch of Ceffect (cefquinome), for the treatment of bacterial infections in cattle and pigs caused by Gram-positive and Gram-negative micro-organisms sensitive to cefquinome.
Ceffect is available as a 25mg/ml suspension for injection of cattle and pigs, and as Ceffect LC, a 75mg intramammary ointment for lactating cows.
In cattle, Ceffect 25mg/ml suspension for injection is licensed for the treatment of respiratory disease caused by Pasteurella multocida and Mannheimia haemolytica, and also for the treatment of digital dermatitis, infectious bulbar necrosis, acute interdigital necrobacillosis, and acute E.coli mastitis with signs of systemic involvement.
In calves, Ceffect 25mg/ml suspension for injection is licensed for the treatment of E.coli septicaemia
In pigs, Ceffect 25mg/ml suspension for injection targets cefquinome-sensitive organisms including Pasteurella multocida, Haemophilus parasuis, Actinobacillus pleuropneumoniae and Streptococcus suis which can cause bacterial infections of the lungs and respiratory tract. It is also licensed for the treatment of Mastitis-Metritis-Agalactia syndrome (MMA) with involvement of E.coli, Staphylococcus spp., Streptococcus spp. and other cefquinome-sensitive organisms.
In piglets, Ceffect 25mg/ml suspension is licensed for the reduction of mortality in cases of meningitis caused by Streptococcus suis. For the treatment of arthritis caused by Streptococcus spp., E. coli and other cefquinome-sensitive organisms, and epidermitis (mild or moderate lesions) caused by Staphylococcus hyicus.
Ceffect LC, 75mg intramammary ointment for lactating cows also contains cefquinome and comes in individual 8g prefilled syringes for treatment of clinical mastitis caused by Streptococcus uberis, Streptococcus dysgalactiae, Staphylococcus aureus and E. coli, in lactating dairy cows.
For further product information, visit www.noahcompendium.co.uk or contact your local Bayer territory manager.
Bayer Animal Health has launched Remend Wound Spray Gel for cats, dogs and horses.
The new gel contains Remend's structurally modified hyaluronic acid (HA). Bayer says it provides a matrix for cellular events that occur during the proliferative phase of the healing process, which has been shown to enhance healing1, and can promote rapid wound closure
Georgie Hollis BSc from www.vetwoundlibrary.com said: "Managing wounds can be challenging in veterinary practice; the progression of wound healing can be influenced by many factors, and selecting an appropriate product to apply should be based on the needs of the individual wound. A product that provides a moist healing environment and support of the proliferative phase ensures that cellular activity is optimised, helping to improve healing times and minimise scar tissue."
Bayer says Remend Wound Spray Gel is designed for use as part of the overall management of wounds; additional measures such as lavage, debridement and control of infection are equally important, as is giving consideration to any secondary factors that may delay healing if not addressed. The product aims to achieve greater compliance amongst owners by providing an effective management option that is easy to apply. A single application may be sufficient to enhance wound closure in fresh uncomplicated wounds; however more complex wounds may require multiple applications in order to accelerate closure.
For more information, visit: www.vetcentre.bayer.co.uk
Bayer has announced that it has launched a new bone-shaped version of the Drontal Plus tablet with greatly increased palatability to increase client compliance.
In a field study, new Drontal Dog Tasty Bone proved to be voluntarily consumed by 88% of 150 dogs1.
Vicky McAlister, Group Product Manager at Bayer said: "We want to make it as easy as possible for responsible dog owners to remember to worm their pet at least every three months. To help improve compliance, there is an increased necessity for highly palatable oral dosage forms. To meet this need, the Drontal Plus Tasty tablet has been optimised using a novel formula that has an extremely high level of palatability where the majority of dogs take the tablet straight out of the owners hand like a treat - proving that Drontal is now tasty by nature as well as name!
This combined with the memorable bone-shaped design will help cement Drontal as the wormer of choice in the minds of owners."
Is it just me, or does the name of this product sound a bit like someone who has ingested a series of words, and then regurgitated them in no particular order? I suppose Drontal Tasty Dog Bone means something else, and Tasty Dog Drontal Bone doesn't really work.